Should direct-acting antiviral be considered for all patients with HCV-related hepatocellular carcinoma?: Reply to correspondence on "Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study"
Clin Mol Hepatol
.
2026 Jan;32(1):e109-e111.
doi: 10.3350/cmh.2025.0257.
Epub 2025 Mar 13.
Authors
Yan Ling Ong
1
,
Apichat Kaewdech
2
,
Yu Jun Wong
1
3
Affiliations
1
Department of Gastroenterology & Hepatology, Changi General Hospital, Singapore.
2
Gastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
3
Duke-NUS Medical School, Singapore.
PMID:
40077999
PMCID:
PMC12835793
DOI:
10.3350/cmh.2025.0257
No abstract available
Keywords:
Direct-acting antiviral; Hepatitis C; Hepatocellular carcinoma; Survival.
Publication types
Comment
Grants and funding
SingHealth Duke-NUS Academic Medical Center
Roche
Roche Diagnostics
Abbott Laboratories
Gilead Sciences